CASI Pharmaceuticals Inc
CASI Pharmaceuticals Inc (CASI) is a very small-cap company (market cap about $26.49M) operating in the healthcare sector with a focus on developing and licensing pharmaceutical products. As a development-stage or speciality biopharma, its value tends to be driven by clinical progress, regulatory milestones and partnership deals rather than steady earnings. That profile typically brings high volatility, limited liquidity and binary outcomes — trial readouts or approvals can move the share price sharply in either direction. Investors should check the company’s most recent filings, cash runway, pipeline updates and any collaboration agreements before forming a view. This summary is general educational information and not personalised advice; small-cap pharma stocks can be suitable only for investors who accept a high risk of capital loss and long time horizons, and who may wish to seek professional financial or tax advice tailored to their circumstances.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying CASI Pharmaceuticals' stock, with a target price of $4 indicating strong growth potential.
Financial Health
CASI Pharmaceuticals is generating solid revenue and cash flow, indicating a healthy business operation.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CASI
U.S.-China Trade Truce | Investment Opportunities
High-level talks between the U.S. and China are underway to prevent the return of tariffs, a critical step for global economic stability. This creates a potential investment opportunity in companies poised to benefit from improved trade relations and the removal of trade barriers.
Published: September 15, 2025
Explore BasketChina's Biopharma Innovators: The Next Global Partnership Wave
Following GSK's major licensing deal with China's Jiangsu Hengrui, a new investment theme is emerging around Chinese pharmaceutical innovators. This theme focuses on other Chinese biopharma companies that are likely to attract similar global partnerships, driving value through their advanced drug development pipelines.
Published: July 28, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Catalysts Ahead
Trial readouts and regulatory steps can move the share price quickly, though outcomes are binary and timelines uncertain.
Partnership Potential
Licensing deals or collaborations can provide funding and validation, but such agreements are unpredictable and not guaranteed.
Small‑cap Considerations
With a market cap of about $26.49M, expect limited liquidity and higher volatility; suitable only for those accepting capital‑loss risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
